Trials / Withdrawn
WithdrawnNCT05471492
Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease
A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN LABEL CHRONIC TREATMENT PERIOD TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PF-06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE CROHN'S DISEASE
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Telavant, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 2a, multicenter, randomized, double-blind, placebo-controlled study examines subcutaneous dose of PF-06480605 150 mg administered every 4 weeks in participants with moderate to severe active Crohn's Disease to characterize safety, efficacy, pharmacokinetics, and immunogenicity
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Investigational Product | PF-06480605 150 mg |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2023-07-30
- Primary completion
- 2026-08-15
- Completion
- 2026-08-15
- First posted
- 2022-07-22
- Last updated
- 2023-10-19
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05471492. Inclusion in this directory is not an endorsement.